THE COVID-19 PANDEMIC IS PUTTING GREAT PRESSURE ON THE NHS. THE HUGE TURNOUT OF UK PATIENTS TO THE LACK OF SPECIFIC SARS-COV-2 THERAPIES LEADS TO A CONSIDERABLE MANAGEMENT OF HOSPITALISED PATIENTS. DUE TO THE NEED FOR EFFECTIVE THERAPIES AGAINST COVID-19, THE REALLOCATION OF DRUGS ALREADY USED IN THE CLINIC IS HIGHLY AUSPICABLE.THE HYPOTHESIS BEHIND THE PROJECT IS THAT IMMUNOSUPPRESSIVE THERAPIES CAN MITIGATE THE RELEASE SYNDROME CITOCHINICO AND THE HYPER-ACTIVATION OF THE IMMUNE SYSTEM RESPONSIBLE FOR TISSUE DAMAGE THAT CAUSES SEVERE FORMS OF COVID-19. PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES, IN PARTICULAR PATIENTS WITH CHRONIC ARTHRITIS SUCH AS RHEUMATOID ARTHRITIS (AR) AND SERONEGATIVE SPONDYLOARTHRITIS (SPA) ARE A MAJOR PROBLEM DURING THE CURRENT PANDEMIC. IN FACT, THEY HAVE AN AVERAGE TO HIGH DEGREE OF DISABILITY, PRESENT COMORBIDITIES IN MORE THAN 60 % OF CASES AND REQUIRE IMMUNOSUPPRESSIVE TREATMENT.